WO1996041646A3 - Pharmaceutical compositions containing lornoxicam and cyclodextrin - Google Patents

Pharmaceutical compositions containing lornoxicam and cyclodextrin Download PDF

Info

Publication number
WO1996041646A3
WO1996041646A3 PCT/GB1996/001236 GB9601236W WO9641646A3 WO 1996041646 A3 WO1996041646 A3 WO 1996041646A3 GB 9601236 W GB9601236 W GB 9601236W WO 9641646 A3 WO9641646 A3 WO 9641646A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
lornoxicam
pharmaceutical compositions
compositions containing
pharmaceutically acceptable
Prior art date
Application number
PCT/GB1996/001236
Other languages
French (fr)
Other versions
WO1996041646A2 (en
Inventor
John Lawrence Penkler
Darryl Vanstone Whittaker
Original Assignee
Dyer Alison Margaret
Farmarc Nederland Bv
John Lawrence Penkler
Darryl Vanstone Whittaker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyer Alison Margaret, Farmarc Nederland Bv, John Lawrence Penkler, Darryl Vanstone Whittaker filed Critical Dyer Alison Margaret
Priority to AU57747/96A priority Critical patent/AU5774796A/en
Publication of WO1996041646A2 publication Critical patent/WO1996041646A2/en
Publication of WO1996041646A3 publication Critical patent/WO1996041646A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Abstract

A pharmaceutical composition in the form of an aqueous solution or in the form of a product for reconstitution as an aqueous solution, for parenteral or ophthalmic administration, comprises lornoxicam or a pharmaceutically acceptable salt thereof and a cyclodextrin, or an inclusion complex of lornoxicam or a pharmaceutically acceptable salt thereof and a cyclodextrin, and a pharmaceutically acceptable buffer to buffer the solution at a pH in the range of from 6,5 to 9 inclusive. A method for producing the pharmaceutical composition is also disclosed.
PCT/GB1996/001236 1995-06-13 1996-05-23 Pharmaceutical compositions containing lornoxicam and cyclodextrin WO1996041646A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU57747/96A AU5774796A (en) 1995-06-13 1996-05-23 Pharmaceutical compositions containing lornoxicam and cyclod extrin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA954885 1995-06-13
ZA95/4885 1995-06-13

Publications (2)

Publication Number Publication Date
WO1996041646A2 WO1996041646A2 (en) 1996-12-27
WO1996041646A3 true WO1996041646A3 (en) 1997-02-13

Family

ID=25585147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001236 WO1996041646A2 (en) 1995-06-13 1996-05-23 Pharmaceutical compositions containing lornoxicam and cyclodextrin

Country Status (3)

Country Link
AU (1) AU5774796A (en)
WO (1) WO1996041646A2 (en)
ZA (1) ZA964193B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946292B2 (en) 2006-03-28 2015-02-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATA156496A (en) * 1996-09-03 1997-10-15 Nycomed Austria Gmbh PHARMACEUTICAL COMPOSITION
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
AU2003205930B2 (en) * 2002-02-01 2007-08-16 Shimoda Biotech (Pty) Ltd Pharmaceutical composition
BRPI0418474A (en) * 2004-03-10 2007-06-19 Shimoda Biotech Pty Ltd stable parenteral aqueous solution
EP2394641A1 (en) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of lornoxicam
UY38431A (en) * 2018-10-31 2020-05-29 Servier Lab CYCLODEXTRIN-BASED FORMULATION OF A BCL-2 INHIBITOR

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
WO1991011172A1 (en) * 1990-01-23 1991-08-08 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1994002518A1 (en) * 1992-07-27 1994-02-03 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1995032737A1 (en) * 1994-05-27 1995-12-07 Farmarc Nederland Bv Pharmaceutical composition
WO1996014839A1 (en) * 1994-11-15 1996-05-23 Farmarc Nederland Bv Pharmaceutical composition comprising non-steroidal anti-inflammatory drugs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
WO1991011172A1 (en) * 1990-01-23 1991-08-08 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1994002518A1 (en) * 1992-07-27 1994-02-03 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1995032737A1 (en) * 1994-05-27 1995-12-07 Farmarc Nederland Bv Pharmaceutical composition
WO1996014839A1 (en) * 1994-11-15 1996-05-23 Farmarc Nederland Bv Pharmaceutical composition comprising non-steroidal anti-inflammatory drugs

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FROMMING K H: "CYCLODEXTRINE", DEUTSCHE APOTHEKER ZEITUNG, STUTTGART, DE, vol. 127, no. 41, 8 October 1987 (1987-10-08), pages 2040 - 2044, XP000000185 *
J.E.F. REYNOLDS ET AL (ED.): "Martindale, the extra pharmacopoeia", 1993, THE PHARMACEUTICAL PRESS, LONDON, GB, XP002020794 *
LOFTSSON T. ET AL: "Cyclodextrin complexation of NSAIDs: Physicochemical characteristics", EUR. J. PHARM. SCI., 1993, VOL. 1, NO. 2, PAGE(S) 95-101, XP000612132 *
LOFTSSON T. ET AL: "Solubilization and stabilization of drugs through cyclodextrin complexation", ACTA PHARM. NORD., 1991, VOL. 3, NO. 4, PAGE(S) 215-217, XP000612133 *
TAIT, R. J. ET AL: "Characterization of sulfoalkyl ether derivatives of.beta.-cyclodextrin by capillary electrophoresis with indirect UV detection", J. PHARM. BIOMED. ANAL., vol. 10, no. 9, 1992, pages 615 - 922, XP000612110 *
TSAI R.-S. ET AL: "Physicochemical and structural properties of non-steroidal anti-inflammatory oxicams", HELV. CHIM. ACTA, 1993, VOL. 76, NO. 2, PAGE(S) 842-854, XP002020793 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946292B2 (en) 2006-03-28 2015-02-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin

Also Published As

Publication number Publication date
WO1996041646A2 (en) 1996-12-27
AU5774796A (en) 1997-01-09
ZA964193B (en) 1996-12-04

Similar Documents

Publication Publication Date Title
CA2192433A1 (en) Anti-herpesvirus compounds and methods for identyfying, making and using same
HUT37418A (en) Process for producing new 2,2'-imino-bis/ethanol/ derivatives and pharmaceutical compositions sontaining them as active agents
HUT61989A (en) Process for producing 2-deoxy-2,3-didehydro-n-acetylneuraminic acid derivatives and analogs, as well as pharmaceutical compositions comprising same as active ingredient
CA2225601A1 (en) New stable pharmaceutical preparation for producing propellant-free aerosols
AU7939298A (en) An itraconazole exhibiting an improved solubility, a method of preparing the same and a pharmaceutical composition for oral administration comprising the same
AU5309794A (en) Pharmaceutical compositions containing nanocapsules
RO116342B1 (en) Oral liquid pharmaceutical composition
HUP9901652A3 (en) Use of piperidine-carboxylic acid derivatives for producing pharmaceutical compositions suitable for reducing blood glucose
MX9709094A (en) Pharmaceutical formulations of highly lipophilic camptothecin derivatives.
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
HUT55403A (en) Process for producing modified gangliosides and their functional derivatives, as well as pharmaceutical compositions comprising such active ingredient
CA2167912A1 (en) Process for the Preparation of Sufentanil Derivatives by Carbene Addition/Aminolysis of 4-Piperidone
IL118366A0 (en) Vitamin D derivatives a process for the preparation thereof and pharmaceutical compositions containing the same
EP0214659A3 (en) Peptide derivatives, process for the production thereof and pharmaceutical compositions containing same
CA2101648A1 (en) Polysaccharide-protein conjugates
AU5015396A (en) Thiazole and thiadiazole derivatives, their preparation and pharmaceutical compositions useful in the treatment of throm bocytopenia
CA2286511A1 (en) Novel macrolide derivatives
HUT68239A (en) Process for producing inclusion complexes of nimesulide alkali salts with cyclodextrins or cyclodextrin derivatives and pharmaceutical preparations containing them
WO1996041646A3 (en) Pharmaceutical compositions containing lornoxicam and cyclodextrin
HUP9903459A3 (en) Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same
CA2238389A1 (en) Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
CA2179733A1 (en) Anticonvulsant pseudofructopyranose sulfamates
HUT50844A (en) Process for producing new 2'-halogen methylidene, 2'-ethenylidene and 2'-ethinyladenosine derivatives and pharmaceutical compositions comprising same as active ingredient
HUP9901260A3 (en) Optically active phenylpyrimidine derivative as analgesic agent, process for producing it, pharmaceutical composition containing it and its intermediate
HUP9602640A3 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA